At WISDOM, we operate on a continuous learning model. As we gain new insights from the data we collect – as well as breakthroughs in science- we incorporate those findings and update our study processes, operations, and scientific models. In October 2024, we entered a new phase of the study marked by the implementation of a larger genetic test to expand our impact even further.
The Next Gen Test
Our partners at Color have spent nearly a decade pushing the boundaries of delivering care from their early days in genetic testing to their expansion into a comprehensive Virtual Cancer Clinic. Now, they have broadened their testing offered to WISDOM participants to include additional cancer-related genes beyond those associated with breast cancer. The other cancer genes tested are associated with common hereditary cancers, including ovarian, uterine, colorectal, melanoma, pancreatic, stomach and prostate. The change came as a result of phasing out the prior 9-gene test, requiring an update of the panel to remain consistent with standardized testing procedures. While the adoption of the expanded test will not necessarily change participants’ breast cancer risk information, we are glad to be able to provide participants with more information about their overall cancer risk. The list can be found here: https://www.color.com/learn/color-genes#hereditarycancer
Color also provides additional genetic counseling services to support a growing number of participants. For those identified as being at increased risk for hereditary cancers not related to breast cancer, Color provides genetic counseling directly. For those identified as being at increased risk for breast cancer, Color ensures a seamless transition back to our team of geneticists and doctors whose expertise is in breast cancer risk and prevention.
How to Access It
New participants who enrolled in WISDOM’s “personalized group” beginning or after October 2024 will receive the 29-gene hereditary cancer test. In addition, participants who were in WISDOM1.0 and who choose to enroll in WISDOM2.0 (a new opportunity launching in 2025, for those who complete at least 3 years in the first version of the study) will also receive the 29-gene test. For participants who are not yet eligible to receive the 29-gene test through the study, the test can be purchased directly through Color. We recommend speaking with your provider before purchasing any genetic tests to determine which test may be best for you, and whether your insurance or employer may cover the cost. Important to note, the study continues to update and expand our genetic test offerings as we learn more (this is our 2nd expansion in just 1 year). Our procedures will continue to evolve over time, and we remain committed to offering our participants the best-in-class technologies as they become available for research purposes.
Committed to Advancing Cancer Care
The ongoing collaboration of WISDOM and Color is a testament to the power of partnership and innovation in cancer screening, prevention, and care. Color and the WISDOM Study believe that advancing cancer risk assessment requires more than just new technology — it requires breaking down barriers to access. That’s why our collaboration emphasizes making personalized cancer risk assessments available to more women, regardless of their location or background. By providing at-home genetic testing, we’re ensuring that every participant can take advantage of this groundbreaking research and make informed decisions about their health.
Through this partnership, we are working to reshape the future of breast cancer screening. Whether it’s refining risk-based screening strategies, identifying high-risk individuals earlier, or reducing unnecessary interventions, we are committed to improving outcomes for all women. This partnership embodies our vision of a future where cancer care is not just reactive, but proactive — where personalized medicine is the standard, and every woman can receive the care that’s right for her.
Resources to Learn More
For information about WISDOM & Color’s genetic tests and patient resources, visit these links
